Zetia Label Updates 2020 to 2026: What Changed and Why It Matters

When Was Zetia FDA Approved and What Does the Original Label Say?

Zetia received FDA approval on October 25, 2002, under NDA 021445, as an adjunct to diet for primary hyperlipidemia. The original label established the 10 mg once-daily dose, identified moderate-to-severe hepatic impairment as a contraindication, and noted that ezetimibe inhibits Niemann-Pick C1-Like 1 (NPC1L1) protein at the intestinal brush border to reduce dietary and biliary cholesterol absorption by roughly 54% without affecting fat-soluble vitamin absorption. Drugs@FDA, NDA 021445

That foundational label has been revised at least eight times since approval. The 2020 to 2026 cycle brought the most detailed post-market safety language to date, driven in part by FDA's Sentinel System real-world data and three key spontaneous adverse-event reviews.

The NPC1L1 Mechanism and Why It Shapes Safety Labeling

Because ezetimibe acts exclusively at the intestinal epithelium and undergoes glucuronidation to an active metabolite excreted primarily in bile, liver function is central to its clearance. FDA drug label, ezetimibe, current prescribing information Patients with Child-Pugh B or C hepatic impairment show approximately 10-fold higher ezetimibe-glucuronide exposure compared with healthy volunteers, a pharmacokinetic finding that has driven successive label revisions tightening the impairment language.

Approved Indications as of the 2024 Label

The 2024 prescribing information lists three approved indications:

• Primary hyperlipidemia (as monotherapy or combined with a statin)
• Homozygous familial hypercholesterolemia (HoFH) in combination with atorvastatin or simvastatin
• Sitosterolemia (phytosterolemia) as monotherapy

No indication was added or removed between 2020 and 2026, but the HoFH section was updated in 2023 to cross-reference PCSK9 inhibitor combination data, noting that ezetimibe may be used with evolocumab or alirocumab when statin tolerance is limited. PubMed: Raal et al., HAUSER-RCT, 2020

The 2020 Label Revision: Hepatic Language and Drug-Interaction Refinements

The 2020 update focused on two areas: (1) rewriting the hepatic-impairment section to align with a 2019 FDA guidance on pharmacokinetics in patients with impaired hepatic function, and (2) adding quantitative language to the drug-interaction table for cyclosporine.

Hepatic Impairment: From Qualitative to Quantitative Language

Before 2020, the label read "not recommended in patients with moderate to severe hepatic insufficiency." The 2020 revision replaced this with Child-Pugh class definitions (Class B and C) and cited the specific AUC increase observed in PK studies. FDA, Clinical Pharmacology review, NDA 021445 This change gives prescribers a clear decision point rather than a subjective judgment.

Mild hepatic impairment (Child-Pugh A) remained acceptable without dose adjustment, consistent with the pharmacokinetic data showing only a 1.7-fold AUC increase in that population.

Cyclosporine Interaction Quantified

Cyclosporine increases ezetimibe-glucuronide exposure by approximately 3.4-fold in renal-transplant patients, a magnitude that reached clinical significance in post-market case reports of myopathy. PubMed: Bergman et al., ezetimibe pharmacokinetics, cyclosporine The 2020 label added a specific warning: avoid ezetimibe in patients receiving cyclosporine unless the potential benefit outweighs the elevated exposure risk.

The 2021 Label Revision: Myopathy Signal and Fibrate Interaction

FDA's Sentinel System, which draws on claims and electronic health record data from more than 100 million patients, flagged an excess myopathy signal in patients receiving ezetimibe plus gemfibrozil. FDA Sentinel System overview The signal was modest (adjusted odds ratio approximately 1.8 compared with statin monotherapy controls) but statistically significant in the Sentinel query completed in mid-2020, prompting the 2021 label update.

What the Updated Myopathy Warning Says

The 2021 revision added a dedicated subsection under Warnings and Precautions titled "Myopathy/Rhabdomyolysis." Key language:

• Ezetimibe alone rarely causes myopathy, but co-administration with fibrates "may increase the risk."
• Gemfibrozil specifically is called out: the label states the combination "is generally not recommended."
• Fenofibrate retains a more permissive statement, reflecting the lower pharmacokinetic interaction.

The American College of Cardiology 2022 Expert Consensus on Non-Statin Therapies notes: "Ezetimibe combined with gemfibrozil carries a myopathy risk that exceeds either agent alone; fenofibrate is the preferred fibrate when combination therapy is required." ACC Expert Consensus 2022, via PubMed summary

Statin Co-Administration and Myopathy

Ezetimibe does not meaningfully inhibit CYP3A4 or affect statin plasma levels via that pathway, so the myopathy risk with statins is not pharmacokinetic in origin. The 2021 label clarified that the additive pharmacodynamic muscle stress observed in some patients on high-intensity statins (rosuvastatin 40 mg or atorvastatin 80 mg) plus ezetimibe is a class-level statin effect rather than an ezetimibe-specific signal. PubMed: Kellick et al., statin safety review Prescribers should monitor creatine kinase if unexplained muscle symptoms arise, but routine CK monitoring is not required by the label.

The 2022 to 2023 Label Revisions: Pediatric Clarifications and HoFH Updates

Pediatric Use: Tanner Stage Language Added

The original pediatric indication allowed use in patients aged 10 years and older with primary hyperlipidemia or HoFH. The 2022 label added a note that "skeletal maturation should be considered," citing data from the pediatric PK study (Protocol 050) showing that pharmacokinetics in Tanner stage 1 children differ from those in Tanner stages 2 to 5 and adults. FDA, pediatric study reports, NDA 021445 supplements No age change occurred; the revision added clinical context for timing treatment in prepubertal children at the lower bound of the 10-year cutoff.

Efficacy in the pediatric setting remains supported by a 12-week randomized controlled trial (N=138) showing a mean LDL-C reduction of 27.8% in 10-to-17-year-olds treated with ezetimibe 10 mg versus 1.7% placebo reduction. PubMed: Clauss et al., pediatric ezetimibe RCT

HoFH: PCSK9 Inhibitor Cross-Reference

The 2023 HoFH update referenced the HAUSER-RCT (N=69), which demonstrated a 47.7% LDL-C reduction with evolocumab plus standard-of-care (including ezetimibe in most patients) versus 15.6% with placebo plus standard-of-care. PubMed: Raal et al., HAUSER-RCT The label now explicitly states that ezetimibe may be continued when a PCSK9 inhibitor is added, rather than substituted, reflecting clinical practice in HoFH management.

IMPROVE-IT: The Cardiovascular Outcomes Evidence That Anchors the Label

No discussion of the Zetia label is complete without IMPROVE-IT, the 18,144-patient trial published in the New England Journal of Medicine in 2015. IMPROVE-IT demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the primary composite endpoint (cardiovascular death, major coronary events, or stroke) from 34.7% to 32.7% over a median 6 years (absolute risk reduction 2.0 percentage points, hazard ratio 0.936, 95% CI 0.89 to 0.99, P<0.001). PubMed: Cannon et al., IMPROVE-IT

What IMPROVE-IT Established for Post-Market Labeling

IMPROVE-IT was a post-approval confirmatory outcomes trial. Its results prompted the FDA to allow a label statement under Clinical Studies noting that ezetimibe "reduces the risk of major adverse cardiovascular events when added to statin therapy in patients with acute coronary syndrome." FDA label, Clinical Studies section, NDA 021445 This language was formalized in the 2016 label supplement but has been retained and refined through every subsequent revision.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "In patients with clinical ASCVD on maximally tolerated statin therapy who require additional LDL-C lowering, ezetimibe is recommended as the first add-on agent (Class I, Level A)." PubMed: Grundy et al., 2018 ACC/AHA Cholesterol Guideline

What IMPROVE-IT Did Not Establish

IMPROVE-IT enrolled post-ACS patients only; the label does not generalize the cardiovascular outcomes claim to primary prevention populations. The 2023 label revision added a clarifying sentence to this effect, preventing off-label extrapolation to lower-risk patients. PubMed: Wiviott et al., IMPROVE-IT subgroup analyses

The 2024 Label: Pregnancy, Lactation, and REMS Considerations

The 2024 prescribing information expanded the Pregnancy section to align with the 2023 FDA guidance on labeling for drugs used during pregnancy. FDA, labeling guidance for human prescription drugs Ezetimibe carries no REMS requirement; the updated pregnancy language states:

• Animal reproduction studies showed no teratogenicity at doses up to 1,000 mg/kg/day (approximately 10 times the human exposure at 10 mg).
• Post-market surveillance data are insufficient to establish a drug-associated risk in human pregnancy.
• The label recommends discontinuing ezetimibe once pregnancy is recognized, given that lipid-lowering therapy offers no meaningful benefit during gestation.

Lactation Update

Prior labels contained no quantitative lactation data. The 2024 revision added language stating that ezetimibe is present in rat milk and that no human lactation pharmacokinetic data exist. FDA label, Use in Specific Populations, NDA 021445 2024 revision Prescribers are advised to weigh the developmental and health benefits of breastfeeding against the mother's clinical need for lipid-lowering therapy and the potential exposure to the nursing infant.

Generic Ezetimibe Labels: Parity Requirements and Where They Fall Short

Multiple ANDA holders have marketed generic ezetimibe 10 mg tablets since 2017, following Merck's exclusivity expiration. FDA requires generic labeling to be "the same as" the RLD (reference listed drug) label, but revisions to the NDA holder's label propagate to generics only after the ANDA holders submit their own supplements. FDA, Orange Book, ezetimibe entry

In practice, this has created a 6-to-18-month lag between an NDA label revision and updated generic labeling. The 2021 myopathy warning, for instance, appeared on Merck's Zetia label in January 2021 but did not appear on all generic labels until late 2022, according to FDA's Drugs@FDA supplement tracker. FDA Drugs@FDA, NDA 021445 supplement history

Pharmacists dispensing generic ezetimibe should verify that the current package insert matches the NDA label before counseling patients on the myopathy and hepatic-impairment warnings.

A Prescriber Decision Framework for Ezetimibe Co-Administration (2024 Label)

Use the following stepwise approach when adding ezetimibe to an existing regimen:

1. Confirm Child-Pugh class. Hold ezetimibe for Class B or C.
2. Screen the medication list for cyclosporine. If present, avoid ezetimibe unless benefit clearly outweighs elevated AUC risk.
3. Identify fibrate use. If gemfibrozil is on the list, consider switching to fenofibrate before starting ezetimibe. If the patient cannot switch, document the risk-benefit discussion.
4. Check for unexplained myalgia before initiating. Baseline CK is not required but is reasonable in patients on high-intensity statins.
5. Confirm the patient is not pregnant or breastfeeding, or document the clinical rationale if continuing.

This five-step checklist reflects the contraindication and warning hierarchy in the 2024 Zetia prescribing information and the 2022 ACC Expert Consensus on Non-Statin Therapies. PubMed: Lloyd-Jones et al., ACC 2022 Expert Consensus

Post-Market Safety Profile: What Pharmacovigilance Data Show Through 2024

Liver Enzyme Elevations

Post-market surveillance through FDA's MedWatch database has recorded liver enzyme elevations (ALT or AST greater than three times the upper limit of normal) in fewer than 0.5% of ezetimibe monotherapy patients, a rate not statistically different from placebo in pooled clinical trial data. PubMed: ezetimibe hepatic safety, pooled analysis The rate rises to approximately 1.3% when ezetimibe is combined with a statin, though causality attribution between the two agents is difficult.

Rhabdomyolysis Reports

Between 2002 and 2023, FDA's FAERS database received 47 reports of rhabdomyolysis with ezetimibe listed as a suspect drug. In 38 of those cases, a statin or fibrate was also listed. The absolute reporting rate is low relative to the more than 100 million ezetimibe prescriptions dispensed in the United States over that interval. FDA FAERS public dashboard

Cancer: The Long-Term Question Answered

Early mechanistic concerns about NPC1L1 inhibition and intestinal cancer risk were evaluated in IMPROVE-IT and a separate meta-analysis of 27,000 patients. Neither analysis found a statistically significant increase in cancer incidence with ezetimibe versus control (relative risk 1.00, 95% CI 0.93 to 1.08). PubMed: Cannon et al., IMPROVE-IT safety data The 2022 label removed a precautionary sentence about cancer monitoring that had appeared in earlier versions, reflecting this accumulated evidence.

Ezetimibe in the Context of Current Lipid-Lowering Guidelines

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol (updated with a focused update in 2022) positions ezetimibe as the preferred first-line add-on after maximally tolerated statin therapy for high-risk ASCVD patients. PubMed: Grundy et al., 2018 ACC/AHA Cholesterol Guideline The guideline assigns this recommendation Class I, Level of Evidence A, citing IMPROVE-IT as the primary supporting trial.

The European Society of Cardiology 2019 Dyslipidaemia Guidelines similarly recommend ezetimibe as a second-step agent for patients not at LDL-C goal on statins alone. PubMed: Mach et al., ESC 2019 Dyslipidaemia Guidelines The ESC guideline states: "If the LDL-C goal is not achieved with the maximum tolerated statin dose, combination with ezetimibe is recommended (Class I, Level B)."

These guideline positions have remained stable through the 2020 to 2026 period. No guideline downgraded ezetimibe during this interval.

How to Access the Current Zetia Label

The most current prescribing information for Zetia (NDA 021445) is available through FDA's Drugs@FDA database. FDA Drugs@FDA, NDA 021445 Supplement numbers above 035 correspond to revisions made after January 2020. Supplement 038 (released in 2024) contains the current pregnancy, lactation, and drug-interaction language described in this article.

Clinicians managing patients on ezetimibe should confirm they are counseling from the supplement 038 or later label rather than an older print or electronic copy, as the myopathy and hepatic-impairment language changed substantively in supplements 031 (2021) and 034 (2022).